Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer

European Journal of Cancer

Volumn 40, Issue 4, 2004, Pages 508-514

  Veronese, M L ^a   Stevenson, J P ^a   Sun, W ^a   Redlinger, M ^a   Algazy, K ^a   Giantonio, B ^a   Hahn, S ^a   Vaughn, D ^a   Thorn, C ^b   Whitehead, A S ^b   Haller, D G ^a   O'Dwyer, P J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Colorectal cancer; Irinotecan; MTHFR; Non small cell lung cancer; UFT

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; FLUOROPYRIMIDINE; FOLINIC ACID; IRINOTECAN; TEGAFUR; UFT; UNCLASSIFIED DRUG; URACIL;

ADULT; ALOPECIA; ANEMIA; ARTICLE; CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENETIC POLYMORPHISM; HUMAN; LOWER ESOPHAGUS SPHINCTER; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 10744228712     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.10.022     Document Type: Article

References (52)

1. Au J.L., Wu A.T., Friedman M.A., Sadee W. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep. 63:1979;343-350.
2. El Sayed Y.M., Sadee W. Metabolic activation of R,S-1-[tetrahydro-2- furanyl]-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes. Cancer Res. 43:1983;4039-4044.
3. Ho D.H., Covington W.P., Pazdur R.et al. Clinical pharmacology of combined oral uracil and ftorafur. Drug Metab Disp. 20:1992;936-940.
4. Ota K., Taguchi T., Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 22:1988;333-338.
5. Pazdur R., Lassere Y., Diazcanton E., Bready B., Ho D.H. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin - 14-day schedule. Invest New Drugs. 15:1997;123-128.
6. Meropol N.J., Rustum Y.M., Petrelli N.J.et al. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol. 37:1996;581-586.
7. Pazdur R., Lassere Y., Diazcanton E., Bready B., Ho D.H. Phase I trias of uracil-tegafur (UFT) using 5 and 28 day administration schedules - demonstration of schedule dependent toxicities. Anti-Cancer Drugs. 7:1996;728-733.
8. Muggia F.M., Wu X.Y., Spicer D.et al. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin. Cancer Res. 2:1996;1461-1467.
9. Pazdur R., Lassere Y., Rhodes V.et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 12:1994;2296-2300.
10. Saltz L.B., Leichman C.G., Young C.W.et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer. 75:1995;782-785.
11. Gonzales-Baron M., Feliu J., de la Gandara I.et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer. 31A:1995;2215-2219.
12. Creemers J.G., Lun D., Verweiij J.et al. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev. 20:1994;73-96.
13. Rougier P., Bugat R., Douillard J.Y.et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 15:1997;251-260.
14. Rougier P., Cutsem E.V., Bajetta E.et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412.
15. Cunningham D., Pyrhonen S., James R.D.et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
16. Guichard S., Hennebelle I., Bugat R.et al. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem. Pharmacol. 55:1998;667-676.
17. Mans D.R.A., Grivicich I., Peters G.J., Schwartsmann X. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer. 35:1999;1851-1861.
18. Aschele C., Baldo C., Sobrero A.F., Debernardis D., Bornmann W.G., Bertino J.R. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin. Cancer Res. 4:1998;1323-1330.
19. Saltz L.B., Cox J.V., Blanke C.et al. Irinotecan plus fluorouracil and leucovorin for metatstatic colorectal cancer. Irinotecan study group. N Engl J Med. 343:2000;905-914.
20. Douillard J.Y., Cunningham D., Roth A.D.et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet. 355:2000;1041-1047.
21. Armand J.P., Ducreux M., Mahjoubi X.et al. CPT-11 (Irinotecan) in the treatment of colorectal cancer. Eur J Cancer. 31A:1995;1283-1287.
22. Abigerges D., Chabot G.G., Armand J.P., Herart P., Gouyette A., Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 13:1995;210-211.
23. Armand J.P., Terret C., Couteau C., Rixe O. CPT11. The European experience. Ann N Y Acdd Sci. 803:1996;282-291.
24. Pullarkat S.T., Stoehlmacher J., Ghaderi V.et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1:2001;65-70.
25. Zervos P.H., Allen R.H., Thornton D.E.et al. Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Proc Am Soc Clin Oncol. 16:1997;907.
26. Moran R.G., Scanlon K.L. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res. 51:1991;4618-4623.
27. Toffoli G., Veronesi A., Boiocchi M.et al. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Ann Oncol. 22:2000;373-374.
28. Miller A.B., Hoogstraten B., Staquet M.et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
29. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 16:1988;1215.
30. Barbaux S., Kluijtmans L.A., Whitehead A.S. Accurate and rapid multiplex heteroduplexing method for genotyping key enzymes involved in folate/homocysteine metabolism. Clin Chem. 46:2000;907-912.
31. Malik S.T.A., Talbot D., Clarke P.I.et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer. 62:1990;1023-1025.
32. Carmichael J., Papiela T., Radstone D.et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 20:2002;3617-3627.
33. Douillard J.Y., Hoff P.M., Skillings J.R.et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 20:2002;3605-3616.
34. Van Cutsem E., Twelves C., Cassidy J.et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Results of a large phase III study. J Clin Onc. 19:2001;4097-4107.
35. Twelves C. On behalf of the Xeloda Colorectal Cancer Group. capecitabine as first-line treatment in colorectal cancer:pooled data from two large, phase III trials Eur J Cancer. 38(Suppl. 2):2002;S15-S20.
36. Kohne C.H., Cutsem E.V., Wils J.A.et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol. 22:2003;1018.
37. Rothemberg M.L., Meropol N.J., Poplin E.A., Cutsem E.V., Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin. summary findings of an independent panel J Clin Oncol. 19:2001;3801-3807.
38. Grothey A., Jordan K., Kellner O.et al. Randomized phase II trial of capecitabine plus irinotecan (Caplri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol. 22:2003;1022.
39. Twelves C. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology. 16(Suppl. 12):2002;23-26.
40. Kerr D.J., Ten Bokkel Huinink W.W., Ferry D.R.et al. A phase I/II study of CPT-11 in combination with capecitabine as first-line chemotherapy for metastatic colorectal cancer. Proc Am Soc Clin Oncol. 21:2002;643.
41. Kerr D. Capecitabine/irinotecan in colorectal cancer. european early-phase data and planned trials Oncology. 16(Suppl. 12):2002;12-15.
42. Guichard S., Hennebelle I., Bugat R.et al. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem. Pharmacol. 55:1998;667-676.
43. Pavillard V., Formento P., Rostagno P.et al. Combination of irinotecan (CPT-11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem. Pharmacol. 56:1998;1315-1322.
44. Funakoshi S., Aiba K., Shibata H.et al. Enhanced antitumour activity of SN-38, an active metabolite of CPT-11, and 5-fluorouracil combination for human colorectal cancer cell lines. Proc Am Soc Clin Oncol. 12:1993;193.
45. Alonso V., Escudero P., Zorrilla M.et al. Phase I trial of weekly irinotecan combined with UFT as second line treatment for advanced colorectal cancer. Eur J Cancer. 37:2001;2385-2391.
46. Hill M., Mackay H., Cunningham D.et al. Phase I/II study of oral uracil/tegafur (UFT), leucovorin (LV) and irinotecan (CPT-11) in patients with advanced colorectal cancer. Ann Oncol. 11(Suppl. 4):2000;45.
47. Fuchs C.S., Moore M.R., Harker G., Villa L., Rinaldi D., Hecht J.R. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 21:2003;807-814.
48. Stevenson J.P., Redlinger M., Klujtmans L.A.J.et al. Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol. 19:2001;4081-4087.
49. Langer C.J. The role of UFT and the combination of UFT/leucovorin in non small cell lung cancer. Lung Cancer. 34:2001;297-303.
50. Fukuoka M., Niitani H., Suzuki A.et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 10:1992;16-20.
51. Rocha Lima C.M.S., Joppert M.G. Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer. Oncology. 16(Suppl. 9):2002;25-32.
52. Yamazaki H., Hirano A., Funakoshi S.et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) given by 24 hours infusion plus oral uracil/ tegafur (UFT) in patients with lung cancer. Eur J Cancer. 35(Suppl. 4):1999;266.